Use of benzylglycinamide by a HIV-seropositive polysubstance user: The changing pattern of novel psychoactive substance use among youths.
Study Design
- Tipo de estudio
- Case report
- Tamaño de muestra
- 1
- Intervención
- Use of benzylglycinamide by a HIV-seropositive polysubstance user: The changing pattern of novel psychoactive substance use among youths. None
- Comparador
- Placebo
- Dirección del efecto
- Neutral
- Riesgo de sesgo
- Unclear
Abstract
A 24-year old woman with multisubstance use since the age of 13, including opioids and cocaine, and long-standing HIV/HCV seropositivity status, presented with psychosis, agitation, and insomnia at the emergency department of a university hospital. She had been abusive and physically aggressive frequently without specific reasons and was involved in criminal legal cases. She was hospitalized twice. During her first hospital stay she experienced a brief episode of detachment from her environment, similar to episodes reportedly suffered at home. Psychosis had developed following heavy polysubstance abuse. Her mother provided sachets containing benzylglycinamide, a substance with no known psychotropic effects, which were also present in the patient's urine. She was occasionally positive for cannabinoids. She used to buy various novel psychoactive substances (NPSs) from the internet and used experimentally various substances freely made available to her by drug suppliers/dealers. She was unable to explain clearly why she was taking any of the identified NPS. She stated she was taking benzylglycinamide to calm her when smoking synthetic cannabinoids. While it appears that benzylglycinamide is not likely to constitute a novel drug of abuse, her polysubstance use exemplifies trends in NPS use patterns among the youths in the Western world and should alert mental health workers as to the possible dangers of such behavior and its reflection on social behavior and psychopathology.
Used In Evidence Reviews
Similar Papers
Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2017
Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline.
Annual review of pharmacology and toxicology · 2016
MT1 and MT2 Melatonin Receptors: A Therapeutic Perspective.
Molecular medicine reports · 2010
Chamomile: A herbal medicine of the past with bright future.
British journal of pharmacology · 2006
GABA and glycine as neurotransmitters: a brief history.
Journal of pineal research · 2012
Melatonin and its analogs in insomnia and depression.
Journal of psychopharmacology (Oxford, England) · 2005